ResMed Inc.
ResMed Inc. (RMD) Stock Competitors & Peer Comparison
See (RMD) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RMD | $260.26 | +1.55% | 37.8B | 25.66 | $10.10 | +0.90% |
| ISRG | $491.10 | -1.69% | 179B | 63.88 | $7.89 | N/A |
| BDX | $182.88 | +0.22% | 67.2B | 30.29 | $6.12 | +1.78% |
| BDXA | $59.24 | -2.24% | 55.9B | 21.44 | $2.76 | +1.78% |
| ALC | $82.56 | -0.79% | 40.9B | 39.35 | $2.10 | +0.41% |
| MDLN | $49.69 | +4.39% | 40.4B | 72.17 | $0.69 | N/A |
| WST | $241.57 | -0.93% | 17.4B | 35.48 | $6.80 | +0.36% |
| HOLX | $75.38 | +0.32% | 16.8B | 31.30 | $2.41 | N/A |
| COO | $83.04 | -0.76% | 16.7B | 44.96 | $1.87 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +1.78% |
Stock Comparison
RMD vs ISRG Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, ISRG has a market cap of 179B. Regarding current trading prices, RMD is priced at $260.26, while ISRG trades at $491.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas ISRG's P/E ratio is 63.88. In terms of profitability, RMD's ROE is +0.25%, compared to ISRG's ROE of +0.16%. Regarding short-term risk, RMD is less volatile compared to ISRG. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ISRG's competition here
RMD vs BDX Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, BDX has a market cap of 67.2B. Regarding current trading prices, RMD is priced at $260.26, while BDX trades at $182.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas BDX's P/E ratio is 30.29. In terms of profitability, RMD's ROE is +0.25%, compared to BDX's ROE of +0.07%. Regarding short-term risk, RMD is less volatile compared to BDX. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check BDX's competition here
RMD vs BDXA Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, RMD is priced at $260.26, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas BDXA's P/E ratio is 21.44. In terms of profitability, RMD's ROE is +0.25%, compared to BDXA's ROE of +0.07%. Regarding short-term risk, RMD is less volatile compared to BDXA. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check BDXA's competition here
RMD vs ALC Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, ALC has a market cap of 40.9B. Regarding current trading prices, RMD is priced at $260.26, while ALC trades at $82.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas ALC's P/E ratio is 39.35. In terms of profitability, RMD's ROE is +0.25%, compared to ALC's ROE of +0.05%. Regarding short-term risk, RMD is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check ALC's competition here
RMD vs MDLN Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, MDLN has a market cap of 40.4B. Regarding current trading prices, RMD is priced at $260.26, while MDLN trades at $49.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas MDLN's P/E ratio is 72.17. In terms of profitability, RMD's ROE is +0.25%, compared to MDLN's ROE of +0.08%. Regarding short-term risk, RMD is more volatile compared to MDLN. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check MDLN's competition here
RMD vs WST Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, WST has a market cap of 17.4B. Regarding current trading prices, RMD is priced at $260.26, while WST trades at $241.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas WST's P/E ratio is 35.48. In terms of profitability, RMD's ROE is +0.25%, compared to WST's ROE of +0.17%. Regarding short-term risk, RMD is less volatile compared to WST. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check WST's competition here
RMD vs HOLX Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, HOLX has a market cap of 16.8B. Regarding current trading prices, RMD is priced at $260.26, while HOLX trades at $75.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas HOLX's P/E ratio is 31.30. In terms of profitability, RMD's ROE is +0.25%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, RMD is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check HOLX's competition here
RMD vs COO Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, COO has a market cap of 16.7B. Regarding current trading prices, RMD is priced at $260.26, while COO trades at $83.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas COO's P/E ratio is 44.96. In terms of profitability, RMD's ROE is +0.25%, compared to COO's ROE of +0.05%. Regarding short-term risk, RMD is less volatile compared to COO. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check COO's competition here
RMD vs BDXB Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, RMD is priced at $260.26, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas BDXB's P/E ratio is 7.60. In terms of profitability, RMD's ROE is +0.25%, compared to BDXB's ROE of +0.07%. Regarding short-term risk, RMD is less volatile compared to BDXB. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check BDXB's competition here
RMD vs BAX Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, BAX has a market cap of 11.1B. Regarding current trading prices, RMD is priced at $260.26, while BAX trades at $21.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas BAX's P/E ratio is -12.33. In terms of profitability, RMD's ROE is +0.25%, compared to BAX's ROE of -0.12%. Regarding short-term risk, RMD is more volatile compared to BAX. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check BAX's competition here
RMD vs ATR Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, ATR has a market cap of 9.5B. Regarding current trading prices, RMD is priced at $260.26, while ATR trades at $143.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas ATR's P/E ratio is 24.63. In terms of profitability, RMD's ROE is +0.25%, compared to ATR's ROE of +0.15%. Regarding short-term risk, RMD is less volatile compared to ATR. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ATR's competition here
RMD vs MASI Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, RMD is priced at $260.26, while MASI trades at $175.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas MASI's P/E ratio is -38.48. In terms of profitability, RMD's ROE is +0.25%, compared to MASI's ROE of -0.59%. Regarding short-term risk, RMD is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check MASI's competition here
RMD vs RGEN Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, RGEN has a market cap of 7.6B. Regarding current trading prices, RMD is priced at $260.26, while RGEN trades at $134.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas RGEN's P/E ratio is 13568.00. In terms of profitability, RMD's ROE is +0.25%, compared to RGEN's ROE of +0.00%. Regarding short-term risk, RMD is less volatile compared to RGEN. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check RGEN's competition here
RMD vs BLCO Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, BLCO has a market cap of 6.4B. Regarding current trading prices, RMD is priced at $260.26, while BLCO trades at $17.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas BLCO's P/E ratio is -20.87. In terms of profitability, RMD's ROE is +0.25%, compared to BLCO's ROE of -0.06%. Regarding short-term risk, RMD is less volatile compared to BLCO. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check BLCO's competition here
RMD vs AVTR Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, AVTR has a market cap of 6.1B. Regarding current trading prices, RMD is priced at $260.26, while AVTR trades at $8.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas AVTR's P/E ratio is -11.56. In terms of profitability, RMD's ROE is +0.25%, compared to AVTR's ROE of -0.09%. Regarding short-term risk, RMD is more volatile compared to AVTR. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check AVTR's competition here
RMD vs TFX Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, TFX has a market cap of 5.1B. Regarding current trading prices, RMD is priced at $260.26, while TFX trades at $112.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas TFX's P/E ratio is -16.11. In terms of profitability, RMD's ROE is +0.25%, compared to TFX's ROE of -0.08%. Regarding short-term risk, RMD is less volatile compared to TFX. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check TFX's competition here
RMD vs MMSI Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, MMSI has a market cap of 4.9B. Regarding current trading prices, RMD is priced at $260.26, while MMSI trades at $81.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas MMSI's P/E ratio is 42.16. In terms of profitability, RMD's ROE is +0.25%, compared to MMSI's ROE of +0.08%. Regarding short-term risk, RMD is less volatile compared to MMSI. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check MMSI's competition here
RMD vs STVN Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, STVN has a market cap of 4.4B. Regarding current trading prices, RMD is priced at $260.26, while STVN trades at $15.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas STVN's P/E ratio is 26.72. In terms of profitability, RMD's ROE is +0.25%, compared to STVN's ROE of +0.10%. Regarding short-term risk, RMD is less volatile compared to STVN. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check STVN's competition here
RMD vs ICUI Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, RMD is priced at $260.26, while ICUI trades at $154.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas ICUI's P/E ratio is -506.55. In terms of profitability, RMD's ROE is +0.25%, compared to ICUI's ROE of +0.00%. Regarding short-term risk, RMD and ICUI have similar daily volatility (1.53).Check ICUI's competition here
RMD vs WRBY Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, WRBY has a market cap of 2.9B. Regarding current trading prices, RMD is priced at $260.26, while WRBY trades at $22.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas WRBY's P/E ratio is -296.37. In terms of profitability, RMD's ROE is +0.25%, compared to WRBY's ROE of +0.00%. Regarding short-term risk, RMD is less volatile compared to WRBY. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check WRBY's competition here
RMD vs HAE Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, HAE has a market cap of 2.9B. Regarding current trading prices, RMD is priced at $260.26, while HAE trades at $60.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas HAE's P/E ratio is 16.86. In terms of profitability, RMD's ROE is +0.25%, compared to HAE's ROE of +0.20%. Regarding short-term risk, RMD is less volatile compared to HAE. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check HAE's competition here
RMD vs XRAY Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, XRAY has a market cap of 2.5B. Regarding current trading prices, RMD is priced at $260.26, while XRAY trades at $12.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas XRAY's P/E ratio is -2.85. In terms of profitability, RMD's ROE is +0.25%, compared to XRAY's ROE of -0.48%. Regarding short-term risk, RMD is less volatile compared to XRAY. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check XRAY's competition here
RMD vs LMAT Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, LMAT has a market cap of 2.1B. Regarding current trading prices, RMD is priced at $260.26, while LMAT trades at $91.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas LMAT's P/E ratio is 40.06. In terms of profitability, RMD's ROE is +0.25%, compared to LMAT's ROE of +0.15%. Regarding short-term risk, RMD is less volatile compared to LMAT. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check LMAT's competition here
RMD vs ATRC Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, ATRC has a market cap of 1.6B. Regarding current trading prices, RMD is priced at $260.26, while ATRC trades at $32.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas ATRC's P/E ratio is -53.41. In terms of profitability, RMD's ROE is +0.25%, compared to ATRC's ROE of -0.02%. Regarding short-term risk, RMD is less volatile compared to ATRC. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ATRC's competition here
RMD vs KMTS Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, KMTS has a market cap of 1.5B. Regarding current trading prices, RMD is priced at $260.26, while KMTS trades at $26.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas KMTS's P/E ratio is -6.51. In terms of profitability, RMD's ROE is +0.25%, compared to KMTS's ROE of -1.89%. Regarding short-term risk, RMD is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check KMTS's competition here
RMD vs QDEL Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, QDEL has a market cap of 1.5B. Regarding current trading prices, RMD is priced at $260.26, while QDEL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas QDEL's P/E ratio is -1.35. In terms of profitability, RMD's ROE is +0.25%, compared to QDEL's ROE of -0.46%. Regarding short-term risk, RMD is less volatile compared to QDEL. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check QDEL's competition here
RMD vs PLSE Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, PLSE has a market cap of 1.5B. Regarding current trading prices, RMD is priced at $260.26, while PLSE trades at $19.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas PLSE's P/E ratio is -18.79. In terms of profitability, RMD's ROE is +0.25%, compared to PLSE's ROE of -0.73%. Regarding short-term risk, RMD is less volatile compared to PLSE. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check PLSE's competition here
RMD vs AZTA Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, AZTA has a market cap of 1.3B. Regarding current trading prices, RMD is priced at $260.26, while AZTA trades at $28.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas AZTA's P/E ratio is 50.48. In terms of profitability, RMD's ROE is +0.25%, compared to AZTA's ROE of -0.03%. Regarding short-term risk, RMD is less volatile compared to AZTA. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check AZTA's competition here
RMD vs NVCR Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, NVCR has a market cap of 1.3B. Regarding current trading prices, RMD is priced at $260.26, while NVCR trades at $11.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas NVCR's P/E ratio is -7.06. In terms of profitability, RMD's ROE is +0.25%, compared to NVCR's ROE of -0.50%. Regarding short-term risk, RMD is less volatile compared to NVCR. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check NVCR's competition here
RMD vs BLFS Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, BLFS has a market cap of 1.1B. Regarding current trading prices, RMD is priced at $260.26, while BLFS trades at $22.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas BLFS's P/E ratio is -60.76. In terms of profitability, RMD's ROE is +0.25%, compared to BLFS's ROE of -0.01%. Regarding short-term risk, RMD is less volatile compared to BLFS. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check BLFS's competition here
RMD vs NNNN Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, NNNN has a market cap of 1.1B. Regarding current trading prices, RMD is priced at $260.26, while NNNN trades at $24.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas NNNN's P/E ratio is 411.67. In terms of profitability, RMD's ROE is +0.25%, compared to NNNN's ROE of +0.11%. Regarding short-term risk, RMD is less volatile compared to NNNN. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check NNNN's competition here
RMD vs STAA Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, STAA has a market cap of 876.7M. Regarding current trading prices, RMD is priced at $260.26, while STAA trades at $17.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas STAA's P/E ratio is -9.06. In terms of profitability, RMD's ROE is +0.25%, compared to STAA's ROE of -0.27%. Regarding short-term risk, RMD is less volatile compared to STAA. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check STAA's competition here
RMD vs ATRI Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, RMD is priced at $260.26, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas ATRI's P/E ratio is 64.50. In terms of profitability, RMD's ROE is +0.25%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, RMD is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check ATRI's competition here
RMD vs ANGO Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, ANGO has a market cap of 462.5M. Regarding current trading prices, RMD is priced at $260.26, while ANGO trades at $11.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas ANGO's P/E ratio is -16.75. In terms of profitability, RMD's ROE is +0.25%, compared to ANGO's ROE of -0.15%. Regarding short-term risk, RMD is more volatile compared to ANGO. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check ANGO's competition here
RMD vs KRMD Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, KRMD has a market cap of 219.6M. Regarding current trading prices, RMD is priced at $260.26, while KRMD trades at $4.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas KRMD's P/E ratio is -59.25. In terms of profitability, RMD's ROE is +0.25%, compared to KRMD's ROE of -0.22%. Regarding short-term risk, RMD is less volatile compared to KRMD. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check KRMD's competition here
RMD vs UTMD Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, UTMD has a market cap of 217.3M. Regarding current trading prices, RMD is priced at $260.26, while UTMD trades at $66.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas UTMD's P/E ratio is 19.49. In terms of profitability, RMD's ROE is +0.25%, compared to UTMD's ROE of +0.10%. Regarding short-term risk, RMD is less volatile compared to UTMD. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check UTMD's competition here
RMD vs OSUR Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, OSUR has a market cap of 201.1M. Regarding current trading prices, RMD is priced at $260.26, while OSUR trades at $2.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas OSUR's P/E ratio is -3.40. In terms of profitability, RMD's ROE is +0.25%, compared to OSUR's ROE of -0.16%. Regarding short-term risk, RMD is less volatile compared to OSUR. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check OSUR's competition here
RMD vs STXS Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, STXS has a market cap of 192.7M. Regarding current trading prices, RMD is priced at $260.26, while STXS trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas STXS's P/E ratio is -7.12. In terms of profitability, RMD's ROE is +0.25%, compared to STXS's ROE of -2.49%. Regarding short-term risk, RMD is less volatile compared to STXS. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check STXS's competition here
RMD vs SMTI Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, SMTI has a market cap of 182.7M. Regarding current trading prices, RMD is priced at $260.26, while SMTI trades at $19.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas SMTI's P/E ratio is -28.40. In terms of profitability, RMD's ROE is +0.25%, compared to SMTI's ROE of -1.28%. Regarding short-term risk, RMD is less volatile compared to SMTI. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check SMTI's competition here
RMD vs NYXH Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, NYXH has a market cap of 172.2M. Regarding current trading prices, RMD is priced at $260.26, while NYXH trades at $4.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas NYXH's P/E ratio is -1.73. In terms of profitability, RMD's ROE is +0.25%, compared to NYXH's ROE of -1.01%. Regarding short-term risk, RMD is less volatile compared to NYXH. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check NYXH's competition here
RMD vs INFU Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, INFU has a market cap of 161.4M. Regarding current trading prices, RMD is priced at $260.26, while INFU trades at $7.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas INFU's P/E ratio is 30.52. In terms of profitability, RMD's ROE is +0.25%, compared to INFU's ROE of +0.10%. Regarding short-term risk, RMD is less volatile compared to INFU. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check INFU's competition here
RMD vs PDEX Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, PDEX has a market cap of 128.9M. Regarding current trading prices, RMD is priced at $260.26, while PDEX trades at $39.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas PDEX's P/E ratio is 11.59. In terms of profitability, RMD's ROE is +0.25%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, RMD is more volatile compared to PDEX. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check PDEX's competition here
RMD vs MBOT Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, MBOT has a market cap of 93.9M. Regarding current trading prices, RMD is priced at $260.26, while MBOT trades at $2.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas MBOT's P/E ratio is -4.58. In terms of profitability, RMD's ROE is +0.25%, compared to MBOT's ROE of -0.37%. Regarding short-term risk, RMD is less volatile compared to MBOT. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check MBOT's competition here
RMD vs AKYA Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, RMD is priced at $260.26, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas AKYA's P/E ratio is -1.34. In terms of profitability, RMD's ROE is +0.25%, compared to AKYA's ROE of -6.72%. Regarding short-term risk, RMD is more volatile compared to AKYA. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check AKYA's competition here
RMD vs ZTEK Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, ZTEK has a market cap of 63.1M. Regarding current trading prices, RMD is priced at $260.26, while ZTEK trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas ZTEK's P/E ratio is -8.40. In terms of profitability, RMD's ROE is +0.25%, compared to ZTEK's ROE of -0.61%. Regarding short-term risk, RMD is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ZTEK's competition here
RMD vs DXR Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, DXR has a market cap of 61.5M. Regarding current trading prices, RMD is priced at $260.26, while DXR trades at $12.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas DXR's P/E ratio is 76.31. In terms of profitability, RMD's ROE is +0.25%, compared to DXR's ROE of +0.05%. Regarding short-term risk, RMD is less volatile compared to DXR. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check DXR's competition here
RMD vs STSS Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, STSS has a market cap of 52.2M. Regarding current trading prices, RMD is priced at $260.26, while STSS trades at $1.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas STSS's P/E ratio is N/A. In terms of profitability, RMD's ROE is +0.25%, compared to STSS's ROE of -0.91%. Regarding short-term risk, RMD is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check STSS's competition here
RMD vs OMIC Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, RMD is priced at $260.26, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas OMIC's P/E ratio is -0.58. In terms of profitability, RMD's ROE is +0.25%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, RMD is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check OMIC's competition here
RMD vs IGAP Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, RMD is priced at $260.26, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas IGAP's P/E ratio is -10.52. In terms of profitability, RMD's ROE is +0.25%, compared to IGAP's ROE of +1.21%. Regarding short-term risk, RMD is less volatile compared to IGAP. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check IGAP's competition here
RMD vs NEPH Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, NEPH has a market cap of 43.4M. Regarding current trading prices, RMD is priced at $260.26, while NEPH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas NEPH's P/E ratio is 29.14. In terms of profitability, RMD's ROE is +0.25%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, RMD is less volatile compared to NEPH. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check NEPH's competition here
RMD vs POCI Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, POCI has a market cap of 34.2M. Regarding current trading prices, RMD is priced at $260.26, while POCI trades at $4.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas POCI's P/E ratio is -5.21. In terms of profitability, RMD's ROE is +0.25%, compared to POCI's ROE of -0.61%. Regarding short-term risk, RMD is less volatile compared to POCI. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check POCI's competition here
RMD vs EKSO Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, EKSO has a market cap of 29.3M. Regarding current trading prices, RMD is priced at $260.26, while EKSO trades at $11.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas EKSO's P/E ratio is -2.08. In terms of profitability, RMD's ROE is +0.25%, compared to EKSO's ROE of -0.91%. Regarding short-term risk, RMD is less volatile compared to EKSO. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check EKSO's competition here
RMD vs SDC Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, RMD is priced at $260.26, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas SDC's P/E ratio is -0.03. In terms of profitability, RMD's ROE is +0.25%, compared to SDC's ROE of -1.96%. Regarding short-term risk, RMD is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check SDC's competition here
RMD vs HBIO Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, HBIO has a market cap of 26.1M. Regarding current trading prices, RMD is priced at $260.26, while HBIO trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas HBIO's P/E ratio is -0.48. In terms of profitability, RMD's ROE is +0.25%, compared to HBIO's ROE of -1.99%. Regarding short-term risk, RMD is less volatile compared to HBIO. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check HBIO's competition here
RMD vs IVC Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, RMD is priced at $260.26, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas IVC's P/E ratio is -0.79. In terms of profitability, RMD's ROE is +0.25%, compared to IVC's ROE of -0.46%. Regarding short-term risk, RMD is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check IVC's competition here
RMD vs ZJYL Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, ZJYL has a market cap of 22.9M. Regarding current trading prices, RMD is priced at $260.26, while ZJYL trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas ZJYL's P/E ratio is 14.63. In terms of profitability, RMD's ROE is +0.25%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, RMD is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ZJYL's competition here
RMD vs MLSS Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, MLSS has a market cap of 20.3M. Regarding current trading prices, RMD is priced at $260.26, while MLSS trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas MLSS's P/E ratio is -2.86. In terms of profitability, RMD's ROE is +0.25%, compared to MLSS's ROE of -1.65%. Regarding short-term risk, RMD is less volatile compared to MLSS. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check MLSS's competition here
RMD vs RVP Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, RVP has a market cap of 20.1M. Regarding current trading prices, RMD is priced at $260.26, while RVP trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas RVP's P/E ratio is -3.05. In terms of profitability, RMD's ROE is +0.25%, compared to RVP's ROE of -0.08%. Regarding short-term risk, RMD is more volatile compared to RVP. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check RVP's competition here
RMD vs RGNT Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, RGNT has a market cap of 16.1M. Regarding current trading prices, RMD is priced at $260.26, while RGNT trades at $4.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas RGNT's P/E ratio is -3.71. In terms of profitability, RMD's ROE is +0.25%, compared to RGNT's ROE of N/A. Regarding short-term risk, RMD is less volatile compared to RGNT. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check RGNT's competition here
RMD vs FEMY Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, FEMY has a market cap of 15.9M. Regarding current trading prices, RMD is priced at $260.26, while FEMY trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas FEMY's P/E ratio is -0.78. In terms of profitability, RMD's ROE is +0.25%, compared to FEMY's ROE of -7.64%. Regarding short-term risk, RMD is less volatile compared to FEMY. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check FEMY's competition here
RMD vs NXGL Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, NXGL has a market cap of 12.9M. Regarding current trading prices, RMD is priced at $260.26, while NXGL trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas NXGL's P/E ratio is -3.36. In terms of profitability, RMD's ROE is +0.25%, compared to NXGL's ROE of -0.55%. Regarding short-term risk, RMD is less volatile compared to NXGL. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check NXGL's competition here
RMD vs NXGLW Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, NXGLW has a market cap of 8.6M. Regarding current trading prices, RMD is priced at $260.26, while NXGLW trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas NXGLW's P/E ratio is -0.08. In terms of profitability, RMD's ROE is +0.25%, compared to NXGLW's ROE of -0.55%. Regarding short-term risk, RMD is less volatile compared to NXGLW. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check NXGLW's competition here
RMD vs LUCY Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, LUCY has a market cap of 5.1M. Regarding current trading prices, RMD is priced at $260.26, while LUCY trades at $1.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas LUCY's P/E ratio is -0.55. In terms of profitability, RMD's ROE is +0.25%, compared to LUCY's ROE of -0.00%. Regarding short-term risk, RMD is less volatile compared to LUCY. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check LUCY's competition here
RMD vs NSTG Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, RMD is priced at $260.26, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas NSTG's P/E ratio is -0.03. In terms of profitability, RMD's ROE is +0.25%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, RMD is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check NSTG's competition here
RMD vs MHUA Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, MHUA has a market cap of 3.2M. Regarding current trading prices, RMD is priced at $260.26, while MHUA trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas MHUA's P/E ratio is 0.32. In terms of profitability, RMD's ROE is +0.25%, compared to MHUA's ROE of +0.06%. Regarding short-term risk, RMD is less volatile compared to MHUA. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check MHUA's competition here
RMD vs GMVD Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, RMD is priced at $260.26, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas GMVD's P/E ratio is -0.01. In terms of profitability, RMD's ROE is +0.25%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, RMD is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check GMVD's competition here
RMD vs GMVDW Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, RMD is priced at $260.26, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas GMVDW's P/E ratio is N/A. In terms of profitability, RMD's ROE is +0.25%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, RMD is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check GMVDW's competition here
RMD vs POAI Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, POAI has a market cap of 1.7M. Regarding current trading prices, RMD is priced at $260.26, while POAI trades at $2.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas POAI's P/E ratio is -0.02. In terms of profitability, RMD's ROE is +0.25%, compared to POAI's ROE of +4.25%. Regarding short-term risk, RMD is more volatile compared to POAI. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check POAI's competition here
RMD vs AVGR Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, RMD is priced at $260.26, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas AVGR's P/E ratio is -0.05. In terms of profitability, RMD's ROE is +0.25%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, RMD is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check AVGR's competition here
RMD vs GCTK Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, GCTK has a market cap of 868.2K. Regarding current trading prices, RMD is priced at $260.26, while GCTK trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas GCTK's P/E ratio is N/A. In terms of profitability, RMD's ROE is +0.25%, compared to GCTK's ROE of -26.59%. Regarding short-term risk, RMD is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check GCTK's competition here
RMD vs LUCYW Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, LUCYW has a market cap of 320.5K. Regarding current trading prices, RMD is priced at $260.26, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas LUCYW's P/E ratio is N/A. In terms of profitability, RMD's ROE is +0.25%, compared to LUCYW's ROE of -0.00%. Regarding short-term risk, RMD is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check LUCYW's competition here
RMD vs WOK Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, WOK has a market cap of 8.1K. Regarding current trading prices, RMD is priced at $260.26, while WOK trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas WOK's P/E ratio is N/A. In terms of profitability, RMD's ROE is +0.25%, compared to WOK's ROE of -0.07%. Regarding short-term risk, RMD is less volatile compared to WOK. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check WOK's competition here
RMD vs IIN Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, IIN has a market cap of 0. Regarding current trading prices, RMD is priced at $260.26, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas IIN's P/E ratio is 226.45. In terms of profitability, RMD's ROE is +0.25%, compared to IIN's ROE of -0.00%. Regarding short-term risk, RMD is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check IIN's competition here
RMD vs HRC Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, HRC has a market cap of 0. Regarding current trading prices, RMD is priced at $260.26, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas HRC's P/E ratio is 41.92. In terms of profitability, RMD's ROE is +0.25%, compared to HRC's ROE of +0.14%. Regarding short-term risk, RMD is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check HRC's competition here
RMD vs ARTC Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, ARTC has a market cap of 0. Regarding current trading prices, RMD is priced at $260.26, while ARTC trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas ARTC's P/E ratio is N/A. In terms of profitability, RMD's ROE is +0.25%, compared to ARTC's ROE of N/A. Regarding short-term risk, RMD is more volatile compared to ARTC. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check ARTC's competition here
RMD vs APR Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, APR has a market cap of 0. Regarding current trading prices, RMD is priced at $260.26, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas APR's P/E ratio is 22.59. In terms of profitability, RMD's ROE is +0.25%, compared to APR's ROE of +9.81%. Regarding short-term risk, RMD is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check APR's competition here
RMD vs ATRS Comparison February 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 37.8B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, RMD is priced at $260.26, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 25.66, whereas ATRS's P/E ratio is 14.95. In terms of profitability, RMD's ROE is +0.25%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, RMD is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check ATRS's competition here